Tim Reilly

Dr. Reilly has extensive expertise in drug development across a range of therapeutic modalities and disease areas, with a proven track record of success in pharmaceutical R&D. Currently, he leads HotSpot's drug development efforts focused on the strategy and operational components of bringing our new molecules into clinical development.

He joined HotSpot from Bristol Myers Squibb, where he held positions of increasing leadership responsibility during his 18-year tenure. Most recently he was Senior Vice President, Early Development Program Leadership, where he oversaw the entire early development portfolio spanning multiple modalities and therapeutic areas and established the overall strategic and operational plans from development candidate identification through Phase 1 and Phase 2 clinical development. He has made significant contributions to well over 150 clinical stage molecules during the course of his career.

Dr. Reilly is the industry representative to the Network Steering Committee of the Experimental Cancer Medicines Centres (ECMC) established by Cancer Research UK, is on the Scientific Advisory Panel of the Melanoma Research Foundation and serves on the External Advisory Panel for the Purdue University Institute for Drug Discovery. In addition, he sits on the Translation Research Council for CureSMA and is co-founder and Chief Scientific Office of a non- profit organization, Spinal Muscular Atrophy Research Team (SMART). He obtained his undergraduate degree from the University of Notre Dame, received his Ph.D. in pharmaceutical sciences from Wayne State University and completed postdoctoral training in toxicology and cellular/molecular immunology at the National Institutes of Health under the mentorship of Dr. Lance Pohl. Tim was also previously a long-standing board-certified Diplomat of the American Board of Toxicology.